Computerized tremor analysis of valproate-induced tremor: A comparative study of controlled-release versus conventional valproate

Epilepsia

Volumn 46, Issue 2, 2005, Pages 320-323

  Rinnerthaler, Martina ^a   Luef, Gerhard ^a   Mueller, Joerg ^a   Seppi, Klaus ^a   Wissel, Joerg ^a   Trinka, Eugen ^a   Bauer, Gerhard ^a   Poewe, Werner ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Computerized tremor analysis; Tremor; Valproate

Indexed keywords

VALPROIC ACID;

ACCELEROMETER; ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; ELECTROMYOGRAPHY; EPILEPSY; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; TREMOR; WRIST;

ACTIVITIES OF DAILY LIVING; ADOLESCENT; ADULT; AGED; ANTICONVULSANTS; DELAYED-ACTION PREPARATIONS; DIAGNOSIS, COMPUTER-ASSISTED; DISABILITY EVALUATION; EPILEPSY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREMOR; VALPROIC ACID;

EID: 13244253920     PISSN: 00139580     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0013-9580.2005.36204.x     Document Type: Article

References (11)

1. Löscher W. Basic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsy. CNS Drugs 2002;16:669-94.
2. Biton V, Mirza W, Montsouris G, et al. Weight change associated with valproate and lamotrigine monotherapy in patients with epilepsy. Neurology 2001;56:172-7.
3. Perucca E. Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience. CNS Drugs 2002;16:695-714.
4. Deckers CL, Hekster YA, Keyser A, et al. Adverse effects in epilepsy therapy: wait and see or go for it? Acta Neurol Scand 1997;95:248-52.
5. Kondo T, Tokinaga N, Suzuki A, et al. Altered pharmacokinetics and metabolism of valproate after replacement of conventional valproate with the slow-release formulation in epileptic patients. Pharmacol Toxicol 2002;90:135-8.
6. Bain PG, Findley LJ, Atchison P, et al. Assessing tremor severity. J Neural Neurosurg Psychiatry 1993;56:868-73.
7. Deuschl G, Bain P, Brin M. Consensus statement of the Movement Disorder Society on Tremor: Ad Hoc Scientific Committee. Mov Disord 1998;13(suppl 3):2-23.
8. Zesiewicz TA, Hauser RA. Phenomenology and treatment of tremor disorders. Neurol Clin 2001;19:651-80,vii.
9. Tatsuhara T, Muro Y, et al. Pharmacokinetics of valproic acid and its metabolites after single oral administration of a sustained-release preparation of sodium valproate (KW- 6066N). Jpn J Pharmacol Ther 1988;19:749-57. [in Japanese, abstract in English].
10. Imaizumi T, Izumi T, Fukuyama Y. A comparative clinical and pharmacokinetic study of a new slow-release versus conventional preparations of valproic acid in children with intractable epilepsy. Brain Dev 1992;14:304-8.
11. Doughty J, Baker GA, Jacoby A, et al. Compliance and satisfaction with switching from an immediate-release to sustained-release formulation of valproate in people with epilepsy. Epilepsy Behav 2003;4:710-6.